Biohit Oyj financials
Biohit Oyj
74370089ATTSNBXJVT29 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €15.7M | €14.3M |
| Employee benefits expense | €4.2M | €4.0M |
| Operating profit (EBIT) | €2.9M | €2.6M |
| Finance costs | €140.0K | €322.0K |
| Profit before tax | €2.9M | €2.9M |
| Income tax expense | €163.0K | €299.0K |
| Profit for the year | €2.7M | €2.6M |
| — attributable to owners | €2.7M | €2.6M |
| Total comprehensive income | €2.7M | €2.6M |
| Per share | ||
| Basic EPS | €18.00 | €17.00 |
| Diluted EPS | €18.00 | €17.00 |
| Free cash flow / share | €-8.96 | €1.22 |
| Cash flow statement | ||
| Net cash from operating activities | -€748.0K | €586.0K |
| Net cash from investing activities | €874.0K | €80.0K |
| Net cash from financing activities | -€286.0K | -€230.0K |
| Lease liability payments | €302.0K | €298.0K |
| Net change in cash | -€159.0K | €435.0K |
| Balance sheet | ||
| Total assets | €19.8M | €15.5M |
| Non-current assets | €10.6M | €4.6M |
| Property, plant & equipment | €355.0K | €171.0K |
| Right-of-use assets | €1.5M | €531.0K |
| Current assets | €9.2M | €11.0M |
| Inventories | €799.0K | €1.0M |
| Trade & other receivables | €3.6M | €3.2M |
| Cash & equivalents | €3.5M | €3.7M |
| Total equity | €14.9M | €12.2M |
| — attributable to owners | €14.9M | €12.2M |
| Non-current liabilities | €1.3M | €293.0K |
| Lease liabilities (non-current) | €1.3M | €284.0K |
| Current liabilities | €3.6M | €3.0M |
| Lease liabilities (current) | €337.0K | €303.0K |
| Deferred tax liabilities | €2.0K | €2.0K |
| Derived metrics | ||
| Free cash flow | -€1.4M | €184.0K |
| Operating margin | 18.6% | 17.9% |
| Net margin | 17.4% | 18.0% |
| Return on equity | 18.3% | 21.1% |
| Cash conversion ratio | -0.27× | 0.23× |
| Capex coverage | -1.22× | 1.46× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | €221.0K | -€130.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | -€4.9M | -€2.3M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €544.0K | €341.0K |
| Adjustments For Finance Income Cost | -€22.0K | €311.0K |
| Adjustments For Income Tax Expense | €163.0K | €299.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | €180.0K | -€150.0K |
| Adjustments For Reconcile Profit Loss | €868.0K | €426.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | €3.0K | -€2.0K |
| Cash Advances and Loans Made To Related Parties | €4.0K | €21.0K |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | €8.0K | €0 |
| Changes In Inventories of Finished Goods and Work In Progress | €233.0K | -€230.0K |
| Comprehensive Income Attributable To Owners of Parent | €2.7M | €2.6M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | €1.4M | €1.6M |
| Current Tax Liabilities Current | €837.0K | €424.0K |
| Deferred Tax Assets | €369.0K | €18.0K |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €544.0K | €341.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€48.0K | €38.0K |
| Equity and Liabilities | €19.8M | €15.5M |
| Finance Income | €118.0K | €633.0K |
| Impairment Loss Impairment Gain and Reversal of Impairment Loss Determined In Accordance With IFRS9 | €155.0K | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €104.0K | €245.0K |
| Increase Decrease In Working Capital | €4.5M | €2.5M |
| Increase Decrease Through Exercise of Options | €16.0K | €68.0K |
| Increase Decrease Through Sharebased Payment Transactions | €25.0K | €127.0K |
| Increase Decrease Through Transfers and Other Changes Equity | €1.0K | €1.0K |
| Intangible Assets Other Than Goodwill | €710.0K | €492.0K |
| Interest Paid Classified As Operating Activities | €63.0K | €35.0K |
| Interest Received Classified As Operating Activities | €317.0K | €377.0K |
| Issued Capital | €2.4M | €2.4M |
| Miscellaneous Other Operating Expense | €2.9M | €2.5M |
| Miscellaneous Other Operating Income | €43.0K | €79.0K |
| Noncurrent Contract Assets | €7.5M | €3.2M |
| Other Adjustments For Noncash Items | €135.0K | €99.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€56.0K | €47.0K |
| Other Comprehensive Income Net of Tax Gains Losses From Investments In Equity Instruments | €23.0K | -€46.0K |
| Other Current Financial Assets | €1.3M | €3.0M |
| Other Noncurrent Financial Assets | €134.0K | €139.0K |
| Other Noncurrent Liabilities | €2.0K | €6.0K |
| Proceeds From Exercise of Options | €16.0K | €68.0K |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €1.6M | €1.5M |
| Purchase of Financial Instruments Classified As Investing Activities | €106.0K | €1.0M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €615.0K | €402.0K |
| Reserve of Exchange Differences On Translation | -€104.0K | -€48.0K |
| Reserve of Gains and Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income | -€1.9M | -€1.9M |
| Retained Earnings | €9.3M | €6.5M |
| Trade and Other Current Payables To Trade Suppliers | €1.0M | €679.0K |
Every line item above is a fact tagged in Biohit Oyj's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.